Black Diamond Magnetron GridLock Review: A Super-Fast, Feather-Light, Screw-Free Carabiner

For those who participate in rope-centered sports or performing arts, the carabiner is one of the most important items you own. It's what keeps you attached to your rope, and thus, your head attached to your spinal column. But locking carabiners have always been unwieldy and hard to manipulate. Black Diamond wants to change that—with magnets. More »

Source: http://feeds.gawker.com/~r/gizmodo/full/~3/LWqydkuJUgA/black-diamond-magnetron-gridlock-review-a-super+fast-feather+light-screw+free-carabiner

stations of the cross nike foamposite galaxy bill maher seabiscuit dingo nba all star weekend malin akerman

kabab.tikka: brenn witt: Earning Ideas - United States - Free For All ...

Best Tips About Home Based Business, Work at Home Jobs, Make Money Online, Internet and Businesses Online, Affiliate Revenue, Auctions, Online Jobs, Part Time Jobs, Email Marketing, PPC Advertising, PPC Publishing, Paid Surveys and Much More Visit: http://www.earnideas.com/ ?

It is ok to contact this poster with commercial interests.

Source: http://www.ffaclassifieds.com/-2/posts/5-Jobs/185-Work-at-Home/213235-Earning-Ideas.html

dharun ravi george clooney arrested ravi leigh espn greg oden st patricks day

Source: http://ismymyype.posterous.com/earning-ideas-united-states-free-for-all-clas

rand paul mark kirk florida gop debate freddie mac kristin cavallari oscar nominations rough riders

Source: http://woodardjon.typepad.com/blog/2012/12/earning-ideas-united-states-free-for-all-classifieds-ffa.html

the duchess spice mike starr ufc 141 fight card gli joseph gordon levitt katy perry russell brand

Source: http://brenn-witt.blogspot.com/2012/12/earning-ideas-united-states-free-for.html

liquidmetal gsa scandal kelis dick clark dies ibogaine jamie moyer bone cancer

Source: http://kababtikka.blogspot.com/2012/12/brenn-witt-earning-ideas-united-states.html

ozzie guillen castro comments phish gluten free diet barry zito mac virus santorum drops out bby

Optimize Your Website Marketing Strategies With These Tips - First

You can expand your audience and greatly increase your profits by Internet marketing. Affiliate marketing can be the way to achieve these goals efficiently. It gives you access to millions of computer users. Your online ads can reach a large customer base, while costing you little. Continue reading for tips on how to optimize your experience with online marketing.

Reduce the amount of Flash that is used on your site. Although this may look great, and provides a flashy scene to your site, this is not something that helps your site get noticed by the search engines. If you are using flash, do not go overboard or ad keywords.

You can boost your own authenticity and standing by offering space on your website for major institutions to advertise in. When you associate yourself with a big name you will build a good name for yourself by association. By doing this, you will increase the number of visitors to your site and make it a primary web destination for them.

TIP! How your site looks and operates is as important as what you are selling. Take time to ensure that your website is error-free to ensure that your visitors are not stuck with a poor experience.

Be certain to follow up with all clients. Try to solicit consumer reviews or surveys within two weeks of purchase.

Change your content around so your customers feel like they are controlling things. That is especially important because the Internet is full of unwanted opinions and spam. Make it clear that their participating is optional in order to boost your credibility.

Order checkout pages should include special deals. You could showcase items that are half off if customers spend over a certain dollar amount, for example. This is an excellent choice for getting rid of excess inventory and boosting sales. It also makes the customer think they are getting a great deal.

TIP! When it comes to products that customers need to periodically replenish, a good way to keep them returning is to offer them a small discount for repeat purchases. This is not only convenient for them but translates to guaranteed sales for you.

Try and see your website through the eyes of your customers. Would they find it simple? Is it fun to read? Can your orders be placed quickly and clearly? It is a waste of time and effort to strive to bring new visitors to your site if your website is uninteresting or the layout is confusing. Potential customers can be turned off by these types of sites, and this can result in lost sales.

Don?t delete stuff that hasn?t yet worked. Some great ideas are simply before their time or need to be rethought and tweaked. The Internet is always changing, and people find new uses for things all the time. So try out new strategies for marketing and think about blending old ones with new ones to see what works for you.

Find something that can serve as your niche and will give your site a unique quality. Niches attract the traffic of people looking for specific products. Getting people to visit your site in the first place is half the battle. Not only will the visitors boost your page ranking, they?ll also check out the rest of your site, too.

TIP! You are fully capable of having a successful internet marketing business right now. You do not need fancy software or any other get rich quick medium; all you need is yourself.

Learn how to use HTML tags. Tags are used to highlight your key content. Search engines see this emphasized content and give it more weight when judging the quality and relevance of your page. Be sure to highlight your critical keywords.

Try exploring mobile marketing. Reaching out to your customers while they are away from their computers can really help boost your sales. Mobile marketing is quickly becoming a necessary component of any successful marketing campaign.

TIP! Solid domain names worth having cost a little extra money. You most likely will not get the domain name that matches your company name.

Be careful not to go to far in advertising spending. You shouldn?t spend your dollars on services that won?t properly benefit your business. Apply SEO techniques yourself for free and consider using AdSense or banner ads for your paid marketing strategies.

You should make sure you know the answer to their inquiries. People visit your site seeking knowledge, and if you can?t provide it to them, they will go elsewhere. Providing them with the information that they are seeking will encourage them to give your their business.

These suggestions will help you and your online business grow and be very profitable. Online marketing, as you can see, has become an indispensable way for modern companies to increase their customer bases and sales volume. Use these tips to improve your Website marketing plan, and enjoy the influx of customers.

TIP! A squeeze page is a great way to build a contact list. This is basically a gateway that solicits website visitors for their email addresses before they continue.

Join me on Facebook:
www.facebook.com/maynaseric

Source: http://www.maynaseric.com/optimize-your-website-marketing-strategies-with-these-tips

truffles truffles alabama vs lsu alabama vs lsu bcs championship game beyonce baby detroit auto show

fosse broker: Boat Transportation | Sports n Recreation Info Center ...

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Source: http://mclennonkgracie55.typepad.com/blog/2012/12/boat-transportation-sports-n-recreation-info-center-rickie-david.html

matt ryan att wireless Mother Jones cars Bacon Number Kate Middleton photos Chi Magazine

Source: http://fosse-broker.blogspot.com/2012/12/boat-transportation-sports-n-recreation.html

jason campbell doobie brothers jennie garth peter facinelli marques colston golden state warriors free agents nfl 2012 milwaukee bucks

Source: http://suhanasharma594.blogspot.com/2012/12/fosse-broker-boat-transportation-sports.html

solar flares 2012 whitney houston will toyota recall northern lights sign of the times keystone pipeline purim

Source: http://interval-recognized.blogspot.com/2012/12/fosse-broker-boat-transportation-sports.html

john derbyshire kinkade thomas kinkade paintings easter bunny navy jet crash virginia beach isiah thomas passover

Source: http://claudian-herero.blogspot.com/2012/12/fosse-broker-boat-transportation-sports.html

buffalo sabres texas news kim mulkey sarah palin today show dallas tornado video 1940 census instagram for android

Source: http://orvalbeck9526.typepad.com/blog/2012/12/fosse-broker-boat-transportation-sports-n-recreation-info-center.html

best super bowl ads chrysler super bowl commercial madonna half time show fiat 500 abarth madonna halftime m i a mia super bowl

John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting

Public release date: 7-Dec-2012
[ | E-mail | Share ]

Contact: Amy Leahing
aleahing@p4strategy.com
305-458-0599
John Theurer Cancer Center

Nearly one-third of the studies will be presented orally at this premier hematology research conference

Hackensack, N.J. (December 6, 2012) Remaining at the forefront of blood cancer research, John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 37 blood cancer studies at the 2012 American Society of Hematology (ASH) Annual Meeting being held in Atlanta from December 8-11.

"The research we are presenting at this year's ASH annual meeting underscores our commitment to bring patients access to promising novel therapies," said Andre Goy, M.D., M.S., who is chairman and director and chief of lymphoma, John Theurer Cancer Center and a Physician member of Regional Cancer Care Associates. "It is an exciting time in oncology given the expanding panoply of new medicines that are currently in development, many of which are taken orally, with less side effects and offering new possibilities to improve our patients quality of life and outcome."

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. Nearly one-third of the presentations showcased at the ASH annual meeting by John Theurer Cancer Center have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, and multi-center and international trials in collaboration with leading cancer institutions such as the National Cancer Institute, Dana-Farber Cancer Institute, Mayo Clinic and MD Anderson.

"John Theurer Cancer Center's early drug discovery program is part of many of the exciting developments at this year's ASH, including second generation proteasome inhibitors, such as oprozomib and lenalidomide, and other emerging agents, such as selective kinase inhibitor GS-1101, BTK inhibitor ibrutinib, and SYK inhibitor fostamatinib," said Dr. Goy.

The research presented by Regional Cancer Care Associates physicians at John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and marrow stem cell transplantation and leukemia. Regional Cancer Care Associates physicians at John Theurer Cancer Center are lead or senior author in 15 studies, including Andre Goy, M.D.; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Tatyana Feldman, M.D., lymphoma oncologist; Stuart Goldberg, M.D., chief, leukemia; Robert Korngold, Ph.D., chief, research; Anthony Mato, M.D., director of our chronic lymphocytic leukemia program; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma.

"We are committed to contributing to blood cancer research through our own investigator-initiated research and collaborating with other institutions," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center and President of Regional Cancer Care Associates. "I want to thank our physicians and research staff for their dedication, as well as all of the patients who participate in our studies."

For those attending the ASH annual meeting, visit John Theurer Cancer Center at Booth 3413. The following are abstracts and presentations at ASH annual meeting from John Theurer Cancer Center. For ongoing updates and complete list of abstracts, please visit jtcancercenter.org/ash2012.

John Theurer Cancer Center 2012 ASH Abstracts:

Lymphoma

• 59 A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL), Andre Goy, MD, Oral Session: Dec. 12, 2012 Time: 1:00 PM
• 471 Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT, Scott Rowley, M.D., Oral session: Dec. 10, 2012 Time: 11:00AM
• 686 The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study, Andre Goy, MD, Oral Session: Dec. 12, 2012 Time: 4:45 PM
• 895 SOX11 Directly Represses Wnt/?-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment, K. Stephen Suh, PH.D., Oral session: Dec. 11, 2012 Time: 7:30AM
• 904 Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up, Andre Goy, MD, Oral Session: Dec. 11, 2012 Time: 8:15 AM
• 905 Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" Study, Andre Goy, MD, Oral Session: Dec. 11, 2012 Time: 8:30 AM
• 1579 Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome, Anthony R. Mato, MD, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 1623 A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma, Andre Goy, MD, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 2728 Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort, Tatyana Feldman, M.D., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 2751 Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib, Andre Goy, MD, Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3120 Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3638 Baseline Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) Expression in Circulating CD15+/CD30+ Cells Correlate with Very Poor Outcome in Hodgkin Lymphoma, Andre Goy, MD, Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3658 Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3659 Outcomes in Adolescents and Young Adults with Hodgkin Lymphoma Treated with and without Radiation Therapy On CCG 5942: A Report From the Children's Oncology Group, Burton Appel, MD, Oral and Poster sesson: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3678 Phase 1b Study of TRU-016, an Anti-CD37 SMIPTM Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma, Tatyana Feldman, M.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4269 Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Multiple Myeloma

• 331 Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression, David S. Siegel, M.D., PH.D., Oral session: Dec. 10, 2012 Time: 7:00AM
• 450 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis, David S. Siegel, M.D., PH.D., Oral session: Dec. 10, 2012 Time: 11:45AM
• 727 MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma, David Siegel, MD, PhD, Oral and Poster session: Dec. 10, 2012 Time: 4:30 PM
• 2962 A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials, David H. Vesole, M.D., PH.D., F.A.C.P., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3104 A Phase I/II Study of Escalating Doses of Thalidomide (Thal) in Conjunction with Bortezomib (Vel) and High Dose Melphalan (Mel) As A Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Patients with Advanced Multiple Myeloma (MM), Scott Rowley, M.D., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 4036 A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4038 MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study, David Siegel, MD, PhD, Oral and Poster session: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4053 Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT), David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4070 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4072 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Stem Cell Transplantation

• 457 Multicenter Study of "off-the-Shelf" Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT), Scott Rowley, M.D., Oral session: Dec. 10, 2012 Time: 10:00AM
• 738 Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome Updated Results of a Treatment IND (T-IND) Expanded Access Protocol, Alfred P. Gillio III, MD, Oral Session: Dec. 10, 2012 Time: 5:45PM
• 1965 Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT), David H. Vesole, M.D., PH.D., F.A.C.P., Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 3041 Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP), Alfred P. Gillio III, MD, Oral and Poster session: Dec 9, 2012 Time: 6:00-8:00PM
• 3054 Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation, Robert Korngold, PhD, Oral and Poster Session: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3710 Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant, Tatyana Feldman, M.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4106 Use of the Immunoproteasome Subunit LMP7 Inhibitor to Ameliorate Gvhd in an MHC-Matched miHA-Disparate Murine Model, Robert Korngold, PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Leukemia

• 1685 Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey, Stuart L. Goldberg, M.D, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 2630 Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles, Stuart L. Goldberg, M.D, Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM

Hematologic Malignancies

• 203 A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies, David S. Siegel, M.D., PH.D., Oral session: Dec. 9, 2012 Time: 5:30PM
• 1936 Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies, Melissa F Baker, APN, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM

###

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at Hackensack University is among the nation's top 50 U.S. News and World Report Best Hospitals for cancer the highest-ranked in New Jersey with this designation. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. The John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, access to clinical trials, compassionate care and medical expertiseall under one roof. Physicians at the John Theurer Cancer Center are members of Regional Cancer Care Associates one of the nation's largest professional hematology/oncology groups. For more information please visit jtcancercenter.org.

Media Contact:

Amy Leahing
305.458.0599
aleahing@p4strategy.com

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 7-Dec-2012
[ | E-mail | Share ]

Contact: Amy Leahing
aleahing@p4strategy.com
305-458-0599
John Theurer Cancer Center

Nearly one-third of the studies will be presented orally at this premier hematology research conference

Hackensack, N.J. (December 6, 2012) Remaining at the forefront of blood cancer research, John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 37 blood cancer studies at the 2012 American Society of Hematology (ASH) Annual Meeting being held in Atlanta from December 8-11.

"The research we are presenting at this year's ASH annual meeting underscores our commitment to bring patients access to promising novel therapies," said Andre Goy, M.D., M.S., who is chairman and director and chief of lymphoma, John Theurer Cancer Center and a Physician member of Regional Cancer Care Associates. "It is an exciting time in oncology given the expanding panoply of new medicines that are currently in development, many of which are taken orally, with less side effects and offering new possibilities to improve our patients quality of life and outcome."

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. Nearly one-third of the presentations showcased at the ASH annual meeting by John Theurer Cancer Center have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, and multi-center and international trials in collaboration with leading cancer institutions such as the National Cancer Institute, Dana-Farber Cancer Institute, Mayo Clinic and MD Anderson.

"John Theurer Cancer Center's early drug discovery program is part of many of the exciting developments at this year's ASH, including second generation proteasome inhibitors, such as oprozomib and lenalidomide, and other emerging agents, such as selective kinase inhibitor GS-1101, BTK inhibitor ibrutinib, and SYK inhibitor fostamatinib," said Dr. Goy.

The research presented by Regional Cancer Care Associates physicians at John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and marrow stem cell transplantation and leukemia. Regional Cancer Care Associates physicians at John Theurer Cancer Center are lead or senior author in 15 studies, including Andre Goy, M.D.; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Tatyana Feldman, M.D., lymphoma oncologist; Stuart Goldberg, M.D., chief, leukemia; Robert Korngold, Ph.D., chief, research; Anthony Mato, M.D., director of our chronic lymphocytic leukemia program; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma.

"We are committed to contributing to blood cancer research through our own investigator-initiated research and collaborating with other institutions," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center and President of Regional Cancer Care Associates. "I want to thank our physicians and research staff for their dedication, as well as all of the patients who participate in our studies."

For those attending the ASH annual meeting, visit John Theurer Cancer Center at Booth 3413. The following are abstracts and presentations at ASH annual meeting from John Theurer Cancer Center. For ongoing updates and complete list of abstracts, please visit jtcancercenter.org/ash2012.

John Theurer Cancer Center 2012 ASH Abstracts:

Lymphoma

• 59 A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL), Andre Goy, MD, Oral Session: Dec. 12, 2012 Time: 1:00 PM
• 471 Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT, Scott Rowley, M.D., Oral session: Dec. 10, 2012 Time: 11:00AM
• 686 The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study, Andre Goy, MD, Oral Session: Dec. 12, 2012 Time: 4:45 PM
• 895 SOX11 Directly Represses Wnt/?-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment, K. Stephen Suh, PH.D., Oral session: Dec. 11, 2012 Time: 7:30AM
• 904 Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up, Andre Goy, MD, Oral Session: Dec. 11, 2012 Time: 8:15 AM
• 905 Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" Study, Andre Goy, MD, Oral Session: Dec. 11, 2012 Time: 8:30 AM
• 1579 Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome, Anthony R. Mato, MD, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 1623 A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma, Andre Goy, MD, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 2728 Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort, Tatyana Feldman, M.D., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 2751 Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib, Andre Goy, MD, Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3120 Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3638 Baseline Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) Expression in Circulating CD15+/CD30+ Cells Correlate with Very Poor Outcome in Hodgkin Lymphoma, Andre Goy, MD, Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3658 Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3659 Outcomes in Adolescents and Young Adults with Hodgkin Lymphoma Treated with and without Radiation Therapy On CCG 5942: A Report From the Children's Oncology Group, Burton Appel, MD, Oral and Poster sesson: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3678 Phase 1b Study of TRU-016, an Anti-CD37 SMIPTM Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma, Tatyana Feldman, M.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4269 Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Multiple Myeloma

• 331 Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression, David S. Siegel, M.D., PH.D., Oral session: Dec. 10, 2012 Time: 7:00AM
• 450 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis, David S. Siegel, M.D., PH.D., Oral session: Dec. 10, 2012 Time: 11:45AM
• 727 MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma, David Siegel, MD, PhD, Oral and Poster session: Dec. 10, 2012 Time: 4:30 PM
• 2962 A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials, David H. Vesole, M.D., PH.D., F.A.C.P., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3104 A Phase I/II Study of Escalating Doses of Thalidomide (Thal) in Conjunction with Bortezomib (Vel) and High Dose Melphalan (Mel) As A Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Patients with Advanced Multiple Myeloma (MM), Scott Rowley, M.D., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 4036 A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4038 MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study, David Siegel, MD, PhD, Oral and Poster session: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4053 Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT), David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4070 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4072 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Stem Cell Transplantation

• 457 Multicenter Study of "off-the-Shelf" Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT), Scott Rowley, M.D., Oral session: Dec. 10, 2012 Time: 10:00AM
• 738 Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome Updated Results of a Treatment IND (T-IND) Expanded Access Protocol, Alfred P. Gillio III, MD, Oral Session: Dec. 10, 2012 Time: 5:45PM
• 1965 Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT), David H. Vesole, M.D., PH.D., F.A.C.P., Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 3041 Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP), Alfred P. Gillio III, MD, Oral and Poster session: Dec 9, 2012 Time: 6:00-8:00PM
• 3054 Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation, Robert Korngold, PhD, Oral and Poster Session: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3710 Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant, Tatyana Feldman, M.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4106 Use of the Immunoproteasome Subunit LMP7 Inhibitor to Ameliorate Gvhd in an MHC-Matched miHA-Disparate Murine Model, Robert Korngold, PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Leukemia

• 1685 Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey, Stuart L. Goldberg, M.D, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 2630 Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles, Stuart L. Goldberg, M.D, Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM

Hematologic Malignancies

• 203 A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies, David S. Siegel, M.D., PH.D., Oral session: Dec. 9, 2012 Time: 5:30PM
• 1936 Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies, Melissa F Baker, APN, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM

###

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at Hackensack University is among the nation's top 50 U.S. News and World Report Best Hospitals for cancer the highest-ranked in New Jersey with this designation. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. The John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, access to clinical trials, compassionate care and medical expertiseall under one roof. Physicians at the John Theurer Cancer Center are members of Regional Cancer Care Associates one of the nation's largest professional hematology/oncology groups. For more information please visit jtcancercenter.org.

Media Contact:

Amy Leahing
305.458.0599
aleahing@p4strategy.com

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2012-12/jtcc-jtc120712.php

doppler radar colorado rockies moonshine news channel 4 radar weather morosini death jacoby ellsbury

Astronaut braces for unprecedented year in space

NASA astronaut Scott Kelley listens to a question about his scheduled mission aboard the International Space Station during a briefing Wednesday, Dec. 5, 2012, at Johnson Space Center in Houston. Kelly and Russian cosmonaut Mikhail Kornienko will spend an entire year aboard the International Space Station beginning in 2015. (AP Photo/David J. Phillip)

NASA astronaut Scott Kelley listens to a question about his scheduled mission aboard the International Space Station during a briefing Wednesday, Dec. 5, 2012, at Johnson Space Center in Houston. Kelly and Russian cosmonaut Mikhail Kornienko will spend an entire year aboard the International Space Station beginning in 2015. (AP Photo/David J. Phillip)

NASA astronaut Scott Kelley answers a question about his scheduled mission aboard the International Space Station during a briefing Wednesday, Dec. 5, 2012, at Johnson Space Center in Houston. Kelly and Russian cosmonaut Mikhail Kornienko will spend an entire year aboard the International Space Station beginning in 2015. (AP Photo/David J. Phillip)

NASA astronaut Scott Kelley answers a question about his scheduled mission aboard the International Space Station during a briefing Wednesday, Dec. 5, 2012, at Johnson Space Center in Houston. Kelly and Russian cosmonaut Mikhail Kornienko will spend an entire year aboard the International Space Station beginning in 2015. (AP Photo/David J. Phillip)

NASA astronaut Scott Kelley listens to a question about his scheduled mission aboard the International Space Station during a briefing Wednesday, Dec. 5, 2012, at Johnson Space Center in Houston. Kelly and Russian cosmonaut Mikhail Kornienko will spend an entire year aboard the International Space Station beginning in 2015. (AP Photo/David J. Phillip)

CAPE CANAVERAL, Fla. (AP) ? NASA astronaut Scott Kelly is already bracing for an unprecedented one-year mission aboard the International Space Station. He figures it will be as grueling as climbing Mount Everest.

"It's fun when you're done with it, not while you're doing it," Kelly said Wednesday, barely a week after being named to the marathon flight along with Russian cosmonaut Mikhail Kornienko.

The mission, set to begin in 2015, is intended as a medical test bed for even longer Mars expeditions in the decades ahead.

Space station life can be routine, Kelly noted during a news conference.

"In the morning, you wake up, you're at work. When you go to sleep, you're also at work. So imagine being in your office for a whole year and you never get to leave," he said. "That is a challenge and it presents its own set of issues, but I think I'm up for it."

As for being off the planet for that long, Kelly said he already knows how he reacts to horrific news while in orbit.

During his five-month space station mission that spanned 2010 and 2011, his sister-in-law, former Rep. Gabrielle Giffords, was shot in an assassination attempt in Tucson, Ariz. She is married to Kelly's identical twin, Mark, who retired as a NASA astronaut last year.

"Certainly, nothing good comes out of anything like this. But as a result, I do know how I respond to something along those lines," he said.

Kelly, 48, a Navy captain, has two daughters from a previous marriage, ages 9 and 18. The youngest, Charlotte, screamed "awesome" when she learned her father was selected for the one-year mission.

Brother Mark was all for it. So was Giffords. When Mark told his wife, she said, "a year in space, that's great," Scott Kelly said in a phone interview with The Associated Press.

Meanwhile, in Russia, Kornienko's wife wept at the news. The 52-year-old cosmonaut, a rocket engineer with one daughter, said he initially had some doubts about taking on such a challenge. He previously spent six months in space.

"A year is a serious time," Kornienko said in Russian. But he said his doubts did not last long, "and actually it was my initiative."

Kelly was among four astronauts on NASA's short list for the assignment. Each had served as a commander aboard the space station, and was able to perform spacewalks and robot arm operations. Medical information also went into the selection: A crew member could not have exceeded his limit for exposure to cosmic radiation, for instance.

Kelly said he has no idea how or why he ended up being chosen. He will set a U.S. space endurance record with this mission. No American has spent more than seven months in space at a time.

Russia, on the other hand, already has experience with yearlong space travel. But it's limited to the old Mir space station and more than a decade has passed.

Four Russian cosmonauts have spent at least one uninterrupted year in space. Another two came close.

The world record ? 14 months in a single mission ? is held by Dr. Valery Polyakov.

"They all are alive and well today. Their health status is quite good for their age," said Dr. Igor Ushakov, director of the Institute for Biological Problems in Moscow.

Ushakov warned that the medical risks will be at least double what they are on the more typical six-month mission.

NASA space station program scientist Julie Robinson expects the two men to come back just fine. They will watch an assortment of multinational crews come and go during their tenure; up to six people live on the orbiting outpost at any one time.

The loss of bone mass is not nearly the problem it used to be in weightlessness because of improved exercise equipment and procedures, she said. The newest concern is impaired vision related to pressure on the brain and spinal cord; in some cases, astronauts suffer vision problems long after their flight.

In a chart held up by the director of Russia's piloted space program, Alexey Krasnov, nearly half the slots were red, indicating medical risks to eventual trips to the moon, asteroids and Mars.

"There are many things we don't know," Krasnov said. "We should take some risks upon ourselves" now before embarking on such ambitious endeavors beyond Earth's orbit.

___

Online:

NASA: http://www.nasa.gov/mission_pages/station/main/index.html

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/b2f0ca3a594644ee9e50a8ec4ce2d6de/Article_2012-12-05-Year%20in%20Space/id-df0efbcdc2ee4aa68276ffc7c73e29b7

kawasaki disease resurrection masters tickets one direction tulsa news scalloped potatoes the ten commandments

Stocks open flat as fiscal cliff angst lingers

3 hrs.

From wire services , NBC News

Wall Street opened flat on Thursday in what could be another choppy session as the progress of fiscal negotiations in Washington continues to determine the market's fate.?

Apple's stock price continued to fall, pressuring Nasdaq futures lower, after slumping 6 percent on Wednesday in its biggest single-day loss in four years.?

The Dow Jones industrial average was down about 15 points at 13,019 shortly after the opening bell Thursday.?

The Standard & Poor's 500 index edged up half a point to 1,410. The Nasdaq composite was down a point at 2,973.?

Budget discussions continued to be a key focus for investors. President Barack Obama said there could be a quick deal to avert the "fiscal cliff" - tax hikes and spending cuts set to begin next year, possibly driving the U.S. economy back into recession - if Republican leaders agree to raise tax rates for those making more than $250,000 a year.?

While Republican leaders in the House of Representatives insist that raising tax rates on the rich is a no-go, some GOP lawmakers now see it as inevitable to avoid the fiscal cliff.?

"The market is going to continue to look for news out of Washington and that is going to be the main driver," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.?

Data showed the number of Americans filing new claims for unemployment benefits fell for a third straight week last week, but still remain too volatile to offer a clear signal on labor market conditions.?

"Everyone was saying that claims had gone up because of Sandy, so it's comforting when you get the confirmation," said Paul Zemsky, head of asset allocation at ING Investment Management in New York.?

"No additional weakness in the economy is showing up in jobless claims."?

Apple's?rank in China's smartphone market fell to No.6 in the third quarter as it faces tougher competition from Chinese brands, research firm IDC said Thursday. Apple's 6.4 percent drop on Wednesday was its worst daily performance since mid December 2008 and dragged down the Nasdaq Composite.?

Garmin shares rose 4.1 percent after Standard & Poor's said it will add the navigation device maker to its S&P 500 index. Garmin will replace R.R.Donnelley & Sons after the close of trading on December 11.?

Several European equity benchmark indexes hit 2012 highs, boosted by hopes a U.S. budget deal will be reached before the year-end, and that the worst of Europe's debt crisis might be over.?

The broad U.S. market seesawed Wednesday, with the S&P 500 dropping into negative territory before it rebounded off the 1,400 level, seen as a key technical support.?

The Associated Press and Reuters contributed to this report.?

Source: http://www.nbcnews.com/business/stocks-open-flat-fiscal-cliff-angst-lingers-1C7466946

north korea missile launch modesto st louis weather guinea bissau google stock google stock china gdp